

Lieping Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5662259/publications.pdf>

Version: 2024-02-01

287
papers

74,409
citations

997

114
h-index

529

266
g-index

336
all docs

336
docs citations

336
times ranked

56515
citing authors

#	ARTICLE	IF	CITATIONS
1	Ablation of T cell-associated PD-1H enhances functionality and promotes adoptive immunotherapy. JCI Insight, 2022, 7, .	5.0	3
2	Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. , 2022, 10, e003532.		8
3	Could Programmed Death-Ligand 1 Copy Number Alterations be a Predictive Biomarker for Immunotherapy Response?. Journal of Thoracic Oncology, 2022, 17, 592-595.	1.1	1
4	Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annual Review of Immunology, 2022, 40, 45-74.	21.8	122
5	The CD8 ⁺ “PILR ⁺ ” interaction maintains CD8 ⁺ T cell quiescence. Science, 2022, 376, 996-1001.	12.6	9
6	When immunotherapy meets surgery in non-small cell lung cancer. Cancer Cell, 2022, 40, 603-605.	16.8	7
7	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery, 2022, 21, 529-540.	46.4	134
8	Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy. Nature Communications, 2021, 12, 951.	12.8	50
9	A Burned-Out CD8 ⁺ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. Cancer Discovery, 2021, 11, 1700-1715.	9.4	86
10	Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology, 2021, 23, 1922-1935.	1.2	33
11	YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment. Scientific Reports, 2021, 11, 13482.	3.3	13
12	Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. Science Translational Medicine, 2021, 13, .	12.4	54
13	Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas. Journal of Neuropathology and Experimental Neurology, 2021, 80, 150-159.	1.7	9
14	An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP ⁺ mononuclear cells and PDGF-BB secretion. Bone Research, 2021, 9, 47.	11.4	20
15	Structural insight into T cell coinhibition by PD-1H (VISTA). Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1648-1657.	7.1	29
16	B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. OncoImmunology, 2020, 9, 1684127.	4.6	30
17	Normalization Cancer Immunotherapy for Melanoma. Journal of Investigative Dermatology, 2020, 140, 1134-1142.	0.7	13
18	Pik3ip1 Is a Negative Immune Regulator that Inhibits Antitumor T-Cell Immunity. Clinical Cancer Research, 2019, 25, 6180-6194.	7.0	32

#	ARTICLE	IF	CITATIONS
19	The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1046-1060.	1.1	52
20	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. <i>Nature Immunology</i> , 2019, 20, 835-851.	14.5	277
21	Dendritic cell-associated B7-H3 suppresses the production of autoantibodies and renal inflammation in a mouse model of systemic lupus erythematosus. <i>Cell Death and Disease</i> , 2019, 10, 393.	6.3	9
22	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 4663-4673.	7.0	210
23	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 4592-4602.	7.0	447
24	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 656-666.	30.7	461
25	The PD-1/PD-L1 Pathway Affects the Expansion and Function of Cytotoxic CD8+ T Cells During an Acute Retroviral Infection. <i>Frontiers in Immunology</i> , 2019, 10, 54.	4.8	35
26	PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	90
27	Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. <i>Cell</i> , 2019, 176, 334-347.e12.	28.9	553
28	CD28H expression identifies resident memory CD8 ⁺ T cells with less cytotoxicity in human peripheral tissues and cancers. <i>Oncot Immunology</i> , 2019, 8, e1538440.	4.6	12
29	Calnexin Impairs the Antitumor Immunity of CD4+ and CD8+ T Cells. <i>Cancer Immunology Research</i> , 2019, 7, 123-135.	3.4	30
30	Human Semaphorin-4A drives Th2 responses by binding to receptor ILT-4. <i>Nature Communications</i> , 2018, 9, 742.	12.8	47
31	B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3126-3131.	7.1	35
32	DKK2 imparts tumor immunity evasion through β -catenin-independent suppression of cytotoxic immune-cell activation. <i>Nature Medicine</i> , 2018, 24, 262-270.	30.7	106
33	B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb. <i>Cellular and Molecular Immunology</i> , 2018, 15, 888-897.	10.5	32
34	A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. <i>Cellular and Molecular Immunology</i> , 2018, 15, 838-845.	10.5	35
35	S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. <i>Oncot Immunology</i> , 2018, 7, e1296996.	4.6	15
36	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1562-1573.	7.0	150

#	ARTICLE	IF	CITATIONS
37	A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. <i>Cell</i> , 2018, 175, 313-326.	28.9	985
38	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2018, 39, 624-631.	6.8	153
39	B7-H1 agonists could prevent disseminated inflammation by desensitizing cell susceptibility to cytotoxic T-cells. <i>Oncoimmunology</i> , 2018, 7, e1504156.	4.6	0
40	B7-H4 Modulates Regulatory CD4+ T Cell Induction and Function via Ligation of a Semaphorin 3a/Plexin A4/Neuropilin-1 Complex. <i>Journal of Immunology</i> , 2018, 201, 897-907.	0.8	34
41	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 4270-4279.	7.0	117
42	Anti-B7-H4. , 2017, , 21-29.		1
43	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. <i>Annals of Oncology</i> , 2017, 28, 1988-1995.	1.2	326
44	Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability. <i>Scientific Reports</i> , 2017, 7, 6086.	3.3	16
45	Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 370-378.	7.0	150
46	Granulocytic myeloid-derived suppressor cells suppress virus-specific CD8+ T cell responses during acute Friend retrovirus infection. <i>Retrovirology</i> , 2017, 14, 42.	2.0	20
47	Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy. <i>JAMA Oncology</i> , 2016, 2, 1403.	7.1	135
48	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. <i>Science Translational Medicine</i> , 2016, 8, 328rv4.	12.4	1,844
49	Neuron-specific SALM5 limits inflammation in the CNS via its interaction with HVEM. <i>Science Advances</i> , 2016, 2, e1500637.	10.3	37
50	Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 994-1001.	0.7	27
51	A monoclonal antibody against KCNK9 K+ channel extracellular domain inhibits tumour growth and metastasis. <i>Nature Communications</i> , 2016, 7, 10339.	12.8	57
52	Anti-“PD-1/PD-L1 therapy of human cancer: past, present, and future. <i>Journal of Clinical Investigation</i> , 2015, 125, 3384-3391.	8.2	1,112
53	Immunosuppressive Microenvironment in Head and Neck Cancer. , 2015, , .		1
54	Consensus nomenclature for CD8 ⁺ T cell phenotypes in cancer. <i>Oncoimmunology</i> , 2015, 4, e998538.	4.6	119

#	ARTICLE	IF	CITATIONS
55	Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7551-7556.	7.1	92
56	PD-1 Suppresses Protective Immunity to <i>Streptococcus pneumoniae</i> through a B Cellâ€“Intrinsic Mechanism. Journal of Immunology, 2015, 194, 2289-2299.	0.8	33
57	Expression of the Novel Costimulatory Molecule B7-H5 in Pancreatic Cancer. Annals of Surgical Oncology, 2015, 22, 1574-1579.	1.5	29
58	Mechanistic Assessment of PD-1H Coinhibitory Receptorâ€“Induced T Cell Tolerance to Allogeneic Antigens. Journal of Immunology, 2015, 194, 5294-5304.	0.8	68
59	PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+ T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+ T Cells. Journal of Immunology, 2015, 194, 5801-5811.	0.8	170
60	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clinical Cancer Research, 2015, 21, 3052-3060.	7.0	198
61	B7H1/CD80 Interaction Augments PD-1â€“Dependent T Cell Apoptosis and Ameliorates Graft-versus-Host Disease. Journal of Immunology, 2015, 194, 560-574.	0.8	61
62	B7-H3 Promotes Pathogenesis of Autoimmune Disease and Inflammation by Regulating the Activity of Different T Cell Subsets. PLoS ONE, 2015, 10, e0130126.	2.5	40
63	PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing. PLoS Pathogens, 2015, 11, e1005224.	4.7	58
64	Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget, 2015, 6, 24990-25002.	1.8	49
65	Programmed Death-1 Pathway in Host Tissues Ameliorates Th17/Th1-Mediated Experimental Chronic Graft-versus-Host Disease. Journal of Immunology, 2014, 193, 2565-2573.	0.8	67
66	Myeloid Cellsâ€™ Evasion of Melanoma Immunity. Journal of Investigative Dermatology, 2014, 134, 2675-2677.	0.7	3
67	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 2014, 5, 5241.	12.8	780
68	CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert. Clinical Cancer Research, 2014, 20, 3-5.	7.0	21
69	Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation. Cancer Journal (Sudbury, Mass), 2014, 20, 256-261.	2.0	131
70	PD-1 as an Immune Modulatory Receptor. Cancer Journal (Sudbury, Mass), 2014, 20, 262-264.	2.0	62
71	From the Guest Editor. Cancer Journal (Sudbury, Mass), 2014, 20, 254-255.	2.0	6
72	Hair Follicle Mesenchyme-Associated PD-L1 Regulates T-Cell Activation Induced Apoptosis: A Potential Mechanism of Immune Privilege. Journal of Investigative Dermatology, 2014, 134, 736-745.	0.7	49

#	ARTICLE	IF	CITATIONS
73	Programmed death ligand-1 expression in non-small cell lung cancer. Laboratory Investigation, 2014, 94, 107-116.	3.7	697
74	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clinical Cancer Research, 2014, 20, 5064-5074.	7.0	2,050
75	Anti-TOSO antibody treatment promotes T cell activation-induced cell death (AICD) in vitro and in vivo. Science Bulletin, 2014, 59, 1374-1385.	1.7	0
76	Tissue-Expressed B7-H1 Critically Controls Intestinal Inflammation. Cell Reports, 2014, 6, 625-632.	6.4	53
77	Targeting CD137 enhances the efficacy of cetuximab. Journal of Clinical Investigation, 2014, 124, 2668-2682.	8.2	154
78	Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell-mediated immunity. Journal of Clinical Investigation, 2014, 124, 1966-1975.	8.2	227
79	B7H1/B7.1 Interaction Alleviate Acute Gvhd in a PD-1 Dependent Manner. Blood, 2014, 124, 2423-2423.	1.4	0
80	Cancer immunotherapy: are we there yet?. Experimental Hematology and Oncology, 2013, 2, 33.	5.0	22
81	Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. Cancer Research, 2013, 73, 1733-1741.	0.9	678
82	Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clinical Cancer Research, 2013, 19, 462-468.	7.0	485
83	Advances in targeting cell surface signalling molecules for immune modulation. Nature Reviews Drug Discovery, 2013, 12, 130-146.	46.4	229
84	Adaptive resistance: A tumor strategy to evade immune attack. European Journal of Immunology, 2013, 43, 576-579.	2.9	17
85	Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Reviews Immunology, 2013, 13, 227-242.	22.7	2,382
86	B7-H5 costimulates human T cells via CD28H. Nature Communications, 2013, 4, 2043.	12.8	148
87	Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. Clinical Cancer Research, 2013, 19, 1021-1034.	7.0	458
88	Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer-Response. Clinical Cancer Research, 2013, 19, 5542-5542.	7.0	313
89	CD137 ligand signaling enhances myelopoiesis during infections. European Journal of Immunology, 2013, 43, 1555-1567.	2.9	16
90	Immunohistochemical Staining of B7-H1 (PD-L1) on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue. Journal of Visualized Experiments, 2013, , .	0.3	28

#	ARTICLE	IF	CITATIONS
91	CD137 Facilitates the Resolution of Acute DSS-Induced Colonic Inflammation in Mice. PLoS ONE, 2013, 8, e73277.	2.5	13
92	Anti-B7-H4. , 2013, , 1-9.		0
93	Host Tissue PD-1 Pathway Contribute To Murine Chronic Graft-Versus-Host Disease Via Th1+Th17+ Cells. Blood, 2013, 122, 3244-3244.	1.4	0
94	Loss of B7-H1 Expression by Recipient Parenchymal Cells Leads to Expansion of Infiltrating Donor CD8+ T Cells and Persistence of Graft-Versus-Host Disease. Journal of Immunology, 2012, 188, 724-734.	0.8	30
95	Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Science Translational Medicine, 2012, 4, 127ra37.	12.4	1,837
96	Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood, 2012, 120, 4772-4782.	1.4	256
97	Safety, Activity, and Immune Correlates of Anti-“PD-1 Antibody in Cancer. New England Journal of Medicine, 2012, 366, 2443-2454.	27.0	10,727
98	The B7 Homologues and their Receptors in Hematologic Malignancies. European Journal of Haematology, 2012, 88, 465-475.	2.2	17
99	Expression of anti-HVEM single-chain antibody on tumor cells induces tumor-specific immunity with long-term memory. Cancer Immunology, Immunotherapy, 2012, 61, 203-214.	4.2	18
100	Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. Journal of Clinical Investigation, 2012, 122, 1066-1075.	8.2	202
101	Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab.. Journal of Clinical Oncology, 2012, 30, 2514-2514.	1.6	2
102	Cell Surface Co-signaling Molecules in the Control of Innate and Adaptive Cancer Immunity. , 2012, , 251-266.		0
103	Anti-PD-1 and Anti-B7-H1/PD-L1 Monoclonal Antibodies. , 2012, , 291-306.		0
104	PD-1:PD-L1(B7-H1) pathway in adaptive resistance: A novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers.. Journal of Clinical Oncology, 2012, 30, 5506-5506.	1.6	1
105	Ex Vivo Expanded Hematopoietic Stem Cells Overcome the MHC Barrier in Allogeneic Transplantation. Cell Stem Cell, 2011, 9, 119-130.	11.1	63
106	B7-H4 Pathway in Islet Transplantation and β -Cell Replacement Therapies. Journal of Transplantation, 2011, 2011, 1-8.	0.5	8
107	CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood, 2011, 117, 2423-2432.	1.4	195
108	B7-H2 Is a Costimulatory Ligand for CD28 in Human. Immunity, 2011, 34, 729-740.	14.3	133

#	ARTICLE	IF	CITATIONS
109	Cell Surface Signaling Molecules in the Control of Immune Responses: A Tide Model. <i>Immunity</i> , 2011, 34, 466-478.	14.3	152
110	The development and functions of CD4+ T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope. <i>Cellular and Molecular Immunology</i> , 2011, 8, 333-340.	10.5	2
111	Host APCs Augment In Vivo Expansion of Donor Natural Regulatory T Cells via B7H1/B7.1 in Allogeneic Recipients. <i>Journal of Immunology</i> , 2011, 186, 2739-2749.	0.8	53
112	Blockade of B7-H1 (Programmed Death Ligand 1) Enhances Humoral Immunity by Positively Regulating the Generation of T Follicular Helper Cells. <i>Journal of Immunology</i> , 2011, 186, 5648-5655.	0.8	118
113	Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models. <i>Journal of Immunology</i> , 2011, 187, 1537-1541.	0.8	196
114	Tissue Parenchymal Cell Expression of B7-H1 Inhibits Infiltrating T Cell Expansion and Prevents Persistence of Graft-Versus-Host Disease. <i>Blood</i> , 2011, 118, 2974-2974.	1.4	0
115	B7-H1 Molecules on Myeloma Cells Induce Aggressive Cell Behavior. <i>Blood</i> , 2011, 118, 474-474.	1.4	0
116	Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. <i>Yale Journal of Biology and Medicine</i> , 2011, 84, 409-21.	0.2	97
117	Crucial roles of B7-H1 and B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific CD4+Foxp3+ regulatory T cells in the establishment of oral tolerance. <i>Blood</i> , 2010, 116, 2266-2276.	1.4	64
118	Interferon- γ and tumor necrosis factor- α induce an immunoinhibitory molecule, B7-H1, via nuclear factor- κ B activation in blasts in myelodysplastic syndromes. <i>Blood</i> , 2010, 116, 1124-1131.	1.4	179
119	B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. <i>Blood</i> , 2010, 116, 1291-1298.	1.4	287
120	Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1223-1233.	4.2	107
121	Structural immunology of costimulatory and coinhibitory molecules. <i>Science China Life Sciences</i> , 2010, 53, 183-189.	4.9	8
122	B7-H1 expression on non-B and non-T cells promotes distinct effects on T and B cell responses in autoimmune arthritis. <i>European Journal of Immunology</i> , 2010, 40, 3117-3127.	2.9	65
123	PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. <i>Nature Immunology</i> , 2010, 11, 535-542.	14.5	583
124	CD137-Mediated Pathogenesis from Chronic Hepatitis to Hepatocellular Carcinoma in Hepatitis B Virus-Transgenic Mice. <i>Journal of Immunology</i> , 2010, 185, 7654-7662.	0.8	48
125	Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. <i>Journal of Clinical Oncology</i> , 2010, 28, 3167-3175.	1.6	2,667
126	Immunobiology of Cancer Therapies Targeting CD137 and B7-H1/PD-1 Cosignal Pathways. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 245-267.	1.1	44

#	ARTICLE	IF	CITATIONS
127	B7-H1-Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses. Journal of Immunology, 2010, 185, 2747-2753.	0.8	120
128	CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood, 2010, 115, 1941-1948.	1.4	45
129	Immunomodulation of NK Cells through 4-1BB (CD137) to Improve the Anti-Lymphoma Activity of Rituximab: Antibody-Based Anti-Lymphoma Synergy. Blood, 2010, 116, 422-422.	1.4	0
130	Turning the Tide of Lymphocyte Costimulation. Journal of Immunology, 2009, 182, 2557-2558.	0.8	4
131	B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2741-2746.	7.1	67
132	Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination. Clinical Cancer Research, 2009, 15, 1507-1509.	7.0	25
133	Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage. Clinical Cancer Research, 2009, 15, 770-777.	7.0	28
134	Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions. Cancer Research, 2009, 69, 8067-8075.	0.9	331
135	Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model Informed by Clinical Data. PLoS Medicine, 2009, 6, e1000166.	8.4	65
136	Target-Dependent B7-H1 Regulation Contributes to Clearance of Central Nervous System Infection and Dampens Morbidity. Journal of Immunology, 2009, 182, 5430-5438.	0.8	70
137	Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma. Clinical Cancer Research, 2009, 15, 6341-6347.	7.0	230
138	Leucocyte-associated immunoglobulin-like receptor-4 is an inhibitory regulator of contact hypersensitivity. Immunology, 2009, 128, 543-555.	4.4	14
139	Fine tuning the immune response through B7-H3 and B7-H4. Immunological Reviews, 2009, 229, 145-151.	6.0	155
140	B7-H4-deficient mice display augmented neutrophil-mediated innate immunity. Blood, 2009, 113, 1759-1767.	1.4	72
141	PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood, 2009, 113, 5811-5818.	1.4	179
142	Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood, 2009, 114, 3101-3112.	1.4	256
143	Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood, 2009, 114, 3431-3438.	1.4	121
144	Interferon- β and Tumor Necrosis Factor- α Induce An Immunoinhibitory Molecule, B7-H1, Via NF- κ B Activation in Blasts of Myelodysplastic Syndromes.. Blood, 2009, 114, 2766-2766.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance. <i>Hepatology</i> , 2008, 47, 296-305.	7.3	242
146	B7-1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis. <i>European Journal of Immunology</i> , 2008, 38, 1734-1744.	2.9	72
147	PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T cell responses in EAE. <i>European Journal of Immunology</i> , 2008, 38, 2706-2717.	2.9	103
148	Inhibitory B7-family molecules in the tumour microenvironment. <i>Nature Reviews Immunology</i> , 2008, 8, 467-477.	22.7	1,399
149	Blockade of endogenous B7-H1 suppresses antibacterial protection after primary <i>Listeria monocytogenes</i> infection. <i>Immunology</i> , 2008, 123, 90-99.	4.4	47
150	Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. <i>Journal of Neuroinflammation</i> , 2008, 5, 48.	7.2	174
151	B7-H1 on Hepatocytes Facilitates Priming of Specific CD8 T Cells But Limits the Specific Recall of Primed Responses. <i>Gastroenterology</i> , 2008, 135, 980-988.	1.3	36
152	Detrimental Contribution of the Immuno-Inhibitor B7-H1 to Rabies Virus Encephalitis. <i>Journal of Immunology</i> , 2008, 180, 7506-7515.	0.8	89
153	Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 376-386.	8.2	277
154	Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection. <i>Journal of Leukocyte Biology</i> , 2008, 83, 755-764.	3.3	44
155	CD137 Is Expressed in Human Atherosclerosis and Promotes Development of Plaque Inflammation in Hypercholesterolemic Mice. <i>Circulation</i> , 2008, 117, 1292-1301.	1.6	188
156	Tumor-Induced Immune Suppression of <i>In vivo</i> Effector T-Cell Priming Is Mediated by the B7-H1/PD-1 Axis and Transforming Growth Factor β^2 . <i>Cancer Research</i> , 2008, 68, 5432-5438.	0.9	66
157	Cutting Edge: IFN- γ Enables APC to Promote Memory Th17 and Abate Th1 Cell Development. <i>Journal of Immunology</i> , 2008, 181, 5842-5846.	0.8	83
158	B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. <i>Blood</i> , 2008, 111, 3635-3643.	1.4	438
159	Radiation-Free Anti-CD3-Conditioning Regimen Maintains Tissue Protection Mechanisms and Prevents GVHD: Role of Tissue Expression of B7H1. <i>Blood</i> , 2008, 112, 62-62.	1.4	3
160	Contribution of B7-H1/PD-1 Co-inhibitory Pathway to T-Cell Dysfunction in Cancer. , 2008, , 29-40.		0
161	Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. <i>Blood</i> , 2007, 110, 186-192.	1.4	169
162	Cytokine-Mediated Disruption of Lymphocyte Trafficking, Hemopoiesis, and Induction of Lymphopenia, Anemia, and Thrombocytopenia in Anti-CD137-Treated Mice. <i>Journal of Immunology</i> , 2007, 178, 4194-4213.	0.8	162

#	ARTICLE	IF	CITATIONS
163	B7-H1 Up-Regulation on Myeloid Dendritic Cells Significantly Suppresses T Cell Immune Function in Patients with Chronic Hepatitis B. <i>Journal of Immunology</i> , 2007, 178, 6634-6641.	0.8	118
164	Effects of Specific Immunotherapy on the B7 Family of Costimulatory Molecules in Allergic Inflammation. <i>Journal of Immunology</i> , 2007, 178, 1931-1937.	0.8	16
165	Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma. <i>Cancer Research</i> , 2007, 67, 8900-8905.	0.9	294
166	Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. <i>Blood</i> , 2007, 110, 180-185.	1.4	209
167	The New B7s: Playing a Pivotal Role in Tumor Immunity. <i>Journal of Immunotherapy</i> , 2007, 30, 251-260.	2.4	178
168	Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. <i>Blood</i> , 2007, 109, 4097-4104.	1.4	66
169	CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. <i>Blood</i> , 2007, 109, 4882-4889.	1.4	77
170	Immunostimulatory monoclonal antibodies for cancer therapy. <i>Nature Reviews Cancer</i> , 2007, 7, 95-106.	28.4	564
171	Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN- γ -induced upregulation of B7-H1 (CD274). <i>FEBS Letters</i> , 2006, 580, 755-762.	2.8	394
172	Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. <i>Trends in Molecular Medicine</i> , 2006, 12, 244-246.	6.7	30
173	Suppression of Human T-Cell Responses to $\gamma\delta$ -Cells by Activation of B7-H4 Pathway. <i>Cell Transplantation</i> , 2006, 15, 399-410.	2.5	41
174	The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. <i>Experimental Hematology</i> , 2006, 34, 888-894.	0.4	47
175	Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells. <i>Journal of Immunology</i> , 2006, 177, 40-44.	0.8	252
176	Modulation of Immune Response by B7 Family Molecules in Tumor Microenvironments. <i>Immunological Investigations</i> , 2006, 35, 395-418.	2.0	14
177	Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma. <i>Cancer Research</i> , 2006, 66, 2442-2450.	0.9	129
178	B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. <i>Journal of Experimental Medicine</i> , 2006, 203, 871-881.	8.5	638
179	Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. <i>Journal of Clinical Investigation</i> , 2006, 116, 1045-1051.	8.2	62
180	Mechanisms of GVL Against a Murine Blast Crisis CML. <i>Blood</i> , 2006, 108, 191-191.	1.4	4

#	ARTICLE	IF	CITATIONS
181	CD137 in the Regulation of T Cell Response to Antigen. , 2006, , 83-96.		0
182	B7-H1 connection of innate and adaptive immunity against tumor dormancy. Blood, 2005, 105, 2242-2243.	1.4	4
183	The Many Sounds of T Lymphocyte Silence. Immunologic Research, 2005, 33, 135-148.	2.9	7
184	Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. Kidney International, 2005, 68, 2091-2102.	5.2	44
185	B7-H3 promotes acute and chronic allograft rejection. European Journal of Immunology, 2005, 35, 428-438.	2.9	91
186	Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer, 2005, 104, 2084-2091.	4.1	166
187	Immune Modulations. , 2005, , 475-490.		0
188	Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms. Frontiers in Bioscience - Landmark, 2005, 10, 2856.	3.0	55
189	In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. Journal of Experimental Medicine, 2005, 201, 1531-1541.	8.5	140
190	Constitutive and Inducible Expression of B7 Family of Ligands by Human Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 280-289.	2.9	129
191	Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS. Journal of Neuroscience, 2005, 25, 2537-2546.	3.6	150
192	Expression of Functional B7-H2 and B7.2 Costimulatory Molecules and Their Prognostic Implications in De novo Acute Myeloid Leukemia. Clinical Cancer Research, 2005, 11, 5708-5717.	7.0	111
193	B7-H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK). FEBS Letters, 2005, 579, 6259-6264.	2.8	35
194	Cigarette Smoke Extract Suppresses Human Dendritic Cell Function Leading to Preferential Induction of Th-2 Priming. Journal of Immunology, 2005, 175, 2684-2691.	0.8	192
195	The Role of Leukemia Derived B7-H1 in Tumor-T-Cell Interactions in Humans.. Blood, 2005, 106, 4566-4566.	1.4	0
196	Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Research, 2005, 65, 1089-96.	0.9	687
197	Immunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity. Cancer Research, 2004, 64, 4965-4972.	0.9	61
198	Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17174-17179.	7.1	723

#	ARTICLE	IF	CITATIONS
199	B7-H3 Enhances Tumor Immunity In Vivo by Costimulating Rapid Clonal Expansion of Antigen-Specific CD8+ Cytolytic T Cells. <i>Journal of Immunology</i> , 2004, 173, 5445-5450.	0.8	163
200	53BP1 is required for class switch recombination. <i>Journal of Cell Biology</i> , 2004, 165, 459-464.	5.2	292
201	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. <i>Nature Medicine</i> , 2004, 10, 942-949.	30.7	4,442
202	Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. <i>Nature Reviews Immunology</i> , 2004, 4, 336-347.	22.7	1,110
203	Interferon- γ enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2004, 155, 172-182.	2.3	249
204	New B7 Family Members with Positive and Negative Costimulatory Function. <i>American Journal of Transplantation</i> , 2004, 4, 8-14.	4.7	33
205	Costimulation-based immunotherapy for head and neck cancer. <i>Current Treatment Options in Oncology</i> , 2004, 5, 27-33.	3.0	12
206	Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. <i>International Journal of Cancer</i> , 2004, 110, 51-60.	5.1	65
207	Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. <i>Microbes and Infection</i> , 2004, 6, 759-766.	1.9	112
208	B7-H1 Determines Accumulation and Deletion of Intrahepatic CD8+ T Lymphocytes. <i>Immunity</i> , 2004, 20, 327-336.	14.3	352
209	Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1. <i>Immunity</i> , 2004, 20, 337-347.	14.3	331
210	Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. <i>Blood</i> , 2004, 103, 177-184.	1.4	105
211	Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. <i>Journal of Clinical Investigation</i> , 2004, 113, 694-700.	8.2	146
212	Control of Autoimmune Diseases by the B7-CD28 Family Molecules. <i>Current Pharmaceutical Design</i> , 2004, 10, 121-128.	1.9	10
213	Immunological Ignorance in Cancer. , 2004, , 87-99.		1
214	Immunology of B7-H1 and Its Roles in Human Diseases. <i>International Journal of Hematology</i> , 2003, 78, 321-328.	1.6	34
215	B7-H1 pathway and its role in the evasion of tumor immunity. <i>Journal of Molecular Medicine</i> , 2003, 81, 281-287.	3.9	249
216	CD137 signaling interferes with activation and function of CD4+CD25+ regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. <i>Cellular Immunology</i> , 2003, 226, 20-29.	3.0	59

#	ARTICLE	IF	CITATIONS
217	Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. <i>Cancer</i> , 2003, 97, 2203-2211.	4.1	35
218	Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. <i>Nature Medicine</i> , 2003, 9, 562-567.	30.7	1,157
219	B7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface1. <i>Biology of Reproduction</i> , 2003, 68, 1496-1504.	2.7	189
220	Differential binding properties of B7-H1 and B7-DC to programmed death-1. <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 672-677.	2.1	181
221	B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity. <i>Immunity</i> , 2003, 18, 849-861.	14.3	623
222	Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation. <i>Journal of Immunology</i> , 2003, 171, 4156-4163.	0.8	163
223	Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction. <i>Journal of Experimental Medicine</i> , 2003, 197, 1083-1091.	8.5	259
224	Expression of the Costimulatory Molecule B7-H2 (Inducible Costimulator Ligand) by Human Airway Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2003, 28, 563-573.	2.9	42
225	Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. <i>FASEB Journal</i> , 2003, 17, 1-16.	0.5	95
226	Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor. <i>Journal of Experimental Medicine</i> , 2003, 198, 31-38.	8.5	144
227	Blocking the Monocyte Chemoattractant Protein-1/CCR2 Chemokine Pathway Induces Permanent Survival of Islet Allografts through a Programmed Death-1 Ligand-1-Dependent Mechanism. <i>Journal of Immunology</i> , 2003, 171, 6929-6935.	0.8	100
228	Naturally Occurring Human IgM Antibody That Binds B7-DC and Potentiates T Cell Stimulation by Dendritic Cells. <i>Journal of Immunology</i> , 2003, 170, 1830-1838.	0.8	65
229	Genomic Organization and Expression Analysis of B7-H4, an Immune Inhibitory Molecule of the B7 Family. <i>Journal of Immunology</i> , 2003, 171, 4650-4654.	0.8	233
230	B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. <i>Blood</i> , 2003, 101, 2514-2520.	1.4	157
231	Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. <i>Journal of Clinical Investigation</i> , 2003, 111, 363-370.	8.2	164
232	B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. <i>Cancer Research</i> , 2003, 63, 6501-5.	0.9	401
233	Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. <i>Cancer Research</i> , 2003, 63, 7462-7.	0.9	312
234	Cross-linking the B7 Family Molecule B7-DC Directly Activates Immune Functions of Dendritic Cells. <i>Journal of Experimental Medicine</i> , 2002, 196, 1393-1398.	8.5	96

#	ARTICLE	IF	CITATIONS
235	Ligand Binding Sites of Inducible Costimulator and High Avidity Mutants with Improved Function. Journal of Experimental Medicine, 2002, 195, 1033-1041.	8.5	27
236	Cutting Edge: Selective Impairment of CD8+ T Cell Function in Mice Lacking the TNF Superfamily Member LIGHT. Journal of Immunology, 2002, 168, 4832-4835.	0.8	88
237	Administration of Agonistic Anti-4-1BB Monoclonal Antibody Leads to the Amelioration of Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2002, 168, 1457-1465.	0.8	184
238	Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells. Journal of Immunology, 2002, 168, 4262-4267.	0.8	216
239	Signaling Through NK Cell-Associated CD137 Promotes Both Helper Function for CD8+ Cytolytic T Cells and Responsiveness to IL-2 But Not Cytolytic Activity. Journal of Immunology, 2002, 169, 4230-4236.	0.8	162
240	Modulation of the Immune Response Through 4-1BB. Advances in Experimental Medicine and Biology, 2002, 465, 355-362.	1.6	40
241	Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Medicine, 2002, 8, 1405-1413.	30.7	171
242	Immunotherapy of human papillomavirus-associated malignancies and the challenges posed by T-CELL tolerance. Frontiers in Bioscience - Landmark, 2002, 7, d853.	3.0	5
243	Antibody gene therapy: Old wine in a new bottle. Nature Medicine, 2002, 8, 333-334.	30.7	6
244	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine, 2002, 8, 793-800.	30.7	4,217
245	Immunoglobulin Fusion Proteins as a Tool for Evaluation of T-Cell Costimulatory Molecules. Molecular Biotechnology, 2002, 21, 259-264.	2.4	10
246	Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Medicine, 2002, 8, 1405-1413.	30.7	58
247	Blockade of LIGHT/LTÎ ² and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. Journal of Clinical Investigation, 2002, 109, 549-557.	8.2	68
248	Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. Journal of Clinical Investigation, 2002, 109, 651-659.	8.2	203
249	Blockade of LIGHT/LTÎ ² and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. Journal of Clinical Investigation, 2002, 109, 549-557.	8.2	32
250	Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. Journal of Clinical Investigation, 2002, 109, 651-659.	8.2	138
251	Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Research, 2002, 62, 1884-9.	0.9	108
252	Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Research, 2002, 62, 3459-65.	0.9	101

#	ARTICLE	IF	CITATIONS
253	Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy. Cancer Research, 2002, 62, 4413-8.	0.9	23
254	IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends in Immunology, 2001, 22, 113-115.	6.8	73
255	B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood, 2001, 97, 1809-1816.	1.4	201
256	RELT, a new member of the tumor necrosis factor receptor superfamily, is selectively expressed in hematopoietic tissues and activates transcription factor NF- κ B. Blood, 2001, 97, 2702-2707.	1.4	59
257	Characterization of a spontaneously arising murine squamous cell carcinoma (SCC VII) as a prerequisite for head and neck cancer immunotherapy. Head and Neck, 2001, 23, 899-906.	2.0	92
258	B7-H3: A costimulatory molecule for T cell activation and IFN- γ production. Nature Immunology, 2001, 2, 269-274.	14.5	856
259	Progressive Depletion of Peripheral B Lymphocytes in 4-1BB (CD137) Ligand/I-E α -Transgenic Mice. Journal of Immunology, 2001, 167, 2671-2676.	0.8	60
260	The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. Journal of Clinical Investigation, 2001, 108, 1771-1780.	8.2	204
261	Enhanced Therapeutic Potential of Adoptive Immunotherapy by In Vitro CD28/4-1BB Costimulation of Tumor-Reactive T Cells Against a Poorly Immunogenic, Major Histocompatibility Complex Class I-Negative A9P Melanoma. Journal of Immunotherapy, 2000, 23, 430-437.	2.4	36
262	Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nature Medicine, 2000, 6, 283-289.	30.7	293
263	In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood, 2000, 95, 2346-2351.	1.4	70
264	Costimulation of α T cells by B7-H2, a B7-like molecule that binds ICOS. Blood, 2000, 96, 2808-2813.	1.4	236
265	Rejection of Disseminated Metastases of Colon Carcinoma by Synergism of IL-12 Gene Therapy and 4-1BB Costimulation. Molecular Therapy, 2000, 2, 39-46.	8.2	81
266	Immunoglobulin Fusion Proteins as a Tool for Evaluation of T-Cell Costimulatory Molecules. , 2000, 45, 247-255.		2
267	LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response. Journal of Immunology, 2000, 164, 4105-4110.	0.8	355
268	Immunomodulatory Gene Therapy With Interleukin 12 and 4-1BB Ligand: Long- Term Remission of Liver Metastases in a Mouse Model. Journal of the National Cancer Institute, 2000, 92, 931-936.	6.3	98
269	T lymphocyte costimulatory molecules in host defense and immunologic diseases. Annals of Allergy, Asthma and Immunology, 2000, 85, 164-176.	1.0	6
270	In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood, 2000, 95, 2346-2351.	1.4	10

#	ARTICLE	IF	CITATIONS
271	Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood, 2000, 96, 2808-2813.	1.4	14
272	Mimotopes of cytolytic T lymphocytes in cancer immunotherapy. Current Opinion in Immunology, 1999, 11, 219-222.	5.5	11
273	B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Medicine, 1999, 5, 1365-1369.	30.7	2,200
274	NK1.1 Cells Express 4-1BB (CDw137) Costimulatory Molecule and Are Required for Tumor Immunity Elicited by Anti-4-1BB Monoclonal Antibodies. Cellular Immunology, 1998, 190, 167-172.	3.0	335
275	Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. European Journal of Immunology, 1998, 28, 1116-1121.	2.9	194
276	Immunological ignorance of silent antigens as an explanation of tumor evasion. Trends in Immunology, 1998, 19, 27-30.	7.5	86
277	Overcoming T Cell Ignorance by Providing Costimulation. Advances in Experimental Medicine and Biology, 1998, , 159-165.	1.6	4
278	Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy. Journal of Experimental Medicine, 1997, 186, 229-238.	8.5	185
279	The role of B7-2 (CD86) in tumour immunity. Expert Opinion on Investigational Drugs, 1997, 6, 677-684.	4.1	3
280	Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Life Sciences, 1997, 60, 2035-2041.	4.3	41
281	Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Medicine, 1997, 3, 682-685.	30.7	830
282	Costimulation of T-cell-mediated tumor immunity. Cancer Chemotherapy and Pharmacology, 1996, 38, S40.	2.3	11
283	Can Co-stimulated Tumor Immunity be Therapeutically Efficacious?. Immunological Reviews, 1995, 145, 123-145.	6.0	80
284	A new look at tumor immunology. Trends in Immunology, 1994, 15, 248.	7.5	1
285	Costimulation of T cells for tumor immunity. Trends in Immunology, 1993, 14, 483-486.	7.5	313
286	Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 1992, 71, 1093-1102.	28.9	1,042
287	Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. , 0, .		1